Recent Clinical Development With Reversible and Selective Amine Oxidase Inhibitors
Moclobemide Twice Daily in the Treatment of Major Depressive Episode
A Comparison of the Efficacy and Tolerability of Moclobemide Given as a Single Daily Dose or in Three Divided Doses per Day for the Treatment of Patients With a Major Depressive Episode (DSM-III-R)
Moclobemide and Tricyclic Antidepressants in Severe Depression
Moclobemide Versus Clomipramine in Depressed Patients in General Practice. A Randomized, Double-Blind, Parallel, Multicenter Study
Moclobemide for Depression
Moclobemide Versus Fluoxetine in the Treatment of Inpatients With Major Depression
A Double-Blind Comparison of Moclobemide and Thioridazine Versus Moclobemide and Placebo in the Treatment of Refractory, Severe Depression
Moclobemide in Continuation Treatment of Major Depressive Episodes
The Therapeutic Potential of Moclobemide, a Reversible Selective Monoamine Oxidase A Inhibitor in Parkinson's Disease
Health-Related Quality of Life in Patients With Major Depression Who Are Treated With Moclobemide
The Behavioral Toxicity of Reversible Inhibitors of Monoamine Oxidase A
Moclobemide Safety